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There is a moderate correlation for urine 3-HAA measurement based on
between HPLC and the biosensor assays (r2¼ 0.47, p¼ 0.0033). Besides, the
3-HAA content within the cultured media of TCCSUP and BFTC905
measured with biosensors signiﬁcantly increased with incubation time
(p < 0.0001). Finally, Patients with urothelial carcinoma of bladder and
upper tract have higher urine 3-HAA levels than those without recurrence
or benign urological disease, such as BPH, or hernia (unpaired t-test,
p ¼ 0.028), except for urolithiasis.
Conclusion: The integrated biosensor exhibited a modest accuracy in
urine 3-HAA detection. Both of urothelial carcinoma of urinary bladder and
upper tract exhibited higher IDO expression and its metabolite 3-HAA in
urine.
MP5-5.
CERAMIDE PROMOTES TNF-a-INDUCED CELL DEATH VIA DECREASING
AKT ACTIVITY IN BLADDER CANCER CELL
Hsiao-Hsien Wang 1, Yu-Chi Tsou 2, Shye-Jye Tang 2. 1 Section of Urology,
Cheng-Hsin Rehabilitation Medical Center, Taipei, Taiwan; 2 Institute of
Bioscience and Biotechnology, National Taiwan Ocean University, Keelung,
Taiwan
Purpose: Bladder cancer, a malignant urinary system tumor, is in the ninth
position of the international cancer charts. The cancer shows a highly
recurrent rate that is around 50%~60%. Therefore, investigating a new
therapy to improve the curing rate of the cancer is important. Nowadays,
Bacillus- Calmette-Guerin (BCG) immune therapy is the most common
way for the treatment of bladder cancer. However, there are around 20 %
patients unable to get any beneﬁt from this, and the main mechanism of
the effect of BCG is still unclear. Since BCG treatment have reported, that
macrophages might be recruited into the bladder to induce cancer cell
death by the pro-inﬂammatory response, we further study the mechanism
of BCG. We used lipopolysaccharide to induce macrophage Raw264.7 for
the generation of condition medium (CM-LPS). Our results demonstrated
that CM-LPS might cause cell death via a caspase-dependent manner in
MBT2 bladder cancer cells. As compared with CM-LPS, TNF-a involved the
cell death. Moreover, TNF-a-induced AKT activation was found in MBT2
cell, implying that the activating AKT may have anti-apoptotic activity.
Since ceramide is generated after inﬂammation, we propose that ceramide
may increase TNF-a-induced cell death in bladder cancer.
Materials and methods: MBT-2 cell were treated with different concen-
trations of TNF-a, ceramide, and then the cell death were analyzed with
MTS analysis and Hoechst3334.2 staining for chromatin condensation. The
mechanisms of the cell death of TNF-a combining with ceramide were
investigated by using western blotting to detect AKT activation.
Results: In our study exhibits that TNF-a had slightly to induce MBT2 cell
death. Moreover, using western blot to analyze AKT expression in bladder
cell were exhibited that ceramide decrease AKT activation. In our study,
ceramide reduced AKT activity, promoted mitochondrial disruption and
dephosphorylated Bad, a BH3 containing pro-apoptotic protein. TNF-a
combining with ceramide exhibited chromatin condensation and DNA
fragmentation by Hochest33342 staining assay. Our ﬁndings suggest that
CM-LPS has the cytotoxic activity via ceramide and TNF-a to elicit cell
death in MBT2 cell.
Conclusions: In this study, we suggest that ceramide were promoted TNF-
a-induced cell death via decreasing AKT activity in bladder cancer cell.
These results are demonstrated that ceramide-mediated AKT inactivation
may play an important role in BCGeinduced cell death in MBT2 bladder
cancer cells. Our ﬁndings suggest that improvement of bladder cancer
therapy will be able to decrease the activation of AKT.
MP5-6.
TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA: CASE
SERIES STUDY IN SINGLE HOSPITAL EXPERIENCE
Tzu-Hsiang Wu 1, Yi-Chia Lin 1,2, Te-Fu Tsai 1,2, Guang-Dar Juang 1,2, Chung-
Hsin Yeh 1,2, Yi-Hung Cheng 1,2, Kuang-Yu Chuo 1, Hung-En Chen 1, Thomas
I.S. Hwang 1,2. 1Division of Urology, Department of Surgery, Shin-Kong WHS
Memorial Hospital, Taipei, Taiwan, ROC; 2Department of Urology, Fu Jen
Catholic University School of Medicine, Taipei, Taiwan, ROCPurpose: Treatment for metastatic renal cell carcinoma (mRCC) has
recently focused on targeted therapy including tyrosine kinase inhibitors
andmTOR inhibitors. Molecular-targeted therapies have been proved to be
effective treatment options. We herein report the outcomes of targeted
therapy for mRCC in our institution.
Materials and methods: From 2010 to 2015, 15 mRCC patients were
identiﬁed in our institute under targeted therapy with a diagnosis of
mRCC. Three targeted agents, namely temsirolimus, sunitinib, and ever-
olimus, were given for patient according to the clinical condition. Sunitinib
and Temsirolimus were served as ﬁrst-line treatment and Everolimus was
the secondeline treatment. Demographics, the interval between diagnosis
of metastasis and targeted therapy, the duration of targeted therapy, side
effects and complications after treatment were collected with a retro-
spective medical record review. Response rate were analyzed according to
RECIST criteria.
Results: Among the 15 patients, 9 were male and 6 were female. The mean
age was 70.3 (35-88) years old. Lung metastasis was noted in 80% (12/15)
of the patient, and other sites of metastasis were also noted, including
lymphnodes, liver, bone and adrenal gland. The mean interval between
diagnosis of metastasis and targeted therapy is 27.5 (1e78) days. The mean
duration of targeted therapy is 268.5 days with temsirolimus, 397.8 days
with sunitinib and 360.3 days with everolimus. The most common side
effect noted in targeted therapy is anemia (100%) in temsirolimus group,
hand-foot mouth syndrome (61.5%) and hypertension (61.5%) in sunitinib
group, and cough (50%) (without radiologic sign of interstitial pneumo-
nitis) in everolimus group. There were 2 patients (2/4) with disease
regression and 2 (2/4) with stationary disease under everolimus usage,
compared with 2 patients (2/12) with disease regression, 5 patients (5/12)
with progression disease and 5 patients in stationary status under suni-
tinib usage. One patient with temsirolimus usage was in disease pro-
gression, and the other was in stationary status.
Conclusion: Targeted therapy prolonged the life of mRCC patients with
tolerable outcome. In our series, the response rate of Everolimus is higher
than expected.
MP5-7.
NEPHRON-SPARING MANAGEMENT (DISTAL URETERECTOMY WITH
REIMPLANTATION OF URETER) FOR CARCINOMA OF DISTAL URETER:
A SINGLE CENTER EXPERIENCE
Yen-Hsi Lee 1,2, Yu-Chi Chen 1, Victor C. Lin 1, Tsan-Jung Yu 1, Hua-Pin
Wang 1, Chao-Yang Jiang 1, Hung-Yu Lin 1, Kelvin Lu 1, Ching-Yu
Huang 1. 1Department of Urology, E-DA Hospital, Taiwan; 2 I-Shou
University, Taiwan
Purpose: Radical nephroureterectomy (NU) with bladder-cuff excision has
been the traditional treatment for UTUC because of its high rate of recur-
rence. However, given the morbidity of nephrectomy and the risk of
developing chronic kidney disease (CKD) or dialysis-dependent renal
failure, a nephron-sparing approach may be preferable in selected
patients.
Materials and methods: We retrospectively analyzed 19 patients from
March 2006 to December 2014 at single center in Southern Taiwan who
underwent distal ureterectomy with reimplantation of ureter and
conﬁrmed to be ureter malignancy (urothelial carcinoma n ¼ 18, squa-
mous cell carcinoma n ¼ 1) on ﬁnal pathology. Outcome measures were
recurrence or distant metastasis, renal function preservation, time to
recurrence and overall survival.
Results: Total 19 patients, 13males, 6 females, andmean age are 69.3 years
old. There are no local recurrence, 9 bladder recurrence (47.4%), 3 distant
metastasis (15.8%), and 2 progression to radical nephroureterectomy
(10.5%). Pathological staging: Tis n¼ 1, Ta n¼ 3, T1 n¼ 2, T2 n¼ 6, T3 n¼ 5.
Low grade n ¼ 3, high grade n ¼ 12. Mean time to recurrence was 12.4
(3e24) months, and mean follow up time was 28.1 (1e90) months. Overall
survival rate is 73.7% (14/19), among them, 4 lost follow up, 1 expired.
Mean pre-op creatinine was 1.61 mg/dl, 1 yr post operation creatinine was
1.56mg/dl.
Conclusion: Distal ureterectomy with reimplantation surgery in our
experience is a feasible option for distal ureter tumor in selected patients
(chronic kidney disease, solitary kidney). Favorable post-operative
.Abstracts / Urological Science 26 (2015) S36eS49 S49outcomes with low local recurrence rate, low rate of progression to NU and
renal function preservation are the beneﬁts.
MP5-8.
HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A SYNERGISTICALLY
RESENSITIZES A GEMCITABINE RESISTANT UROTHELIAL CARCINOMA
CELLS VIA SUPPRESSION OF TG-INTERACTING FACTOR AND AKT
ACTIVATION
Bi-Wen Yeh 1,2, Wei-Ming Li 1,2,3,*, Ching-Chia Li 1,2,4, Wan-Yi Kang 5, Chun-
Nung Huang 1,2, Tzyh-Chyuan Hour 6, Zi-Miao Liu 7, Huei-Sheng
Huang 7,*, Wen-Jeng Wu1,2,8,*. 1Department of Urology, School of
Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung,
Taiwan; 2Department of Urology, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung, Taiwan; 3Department of Urology,
Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan;
4Department of Urology, Kaohsiung Municipal Ta-Tung Hospital,
Kaohsiung, Taiwan; 5Department of Pathology, Kuo General Hospital,
Tainan 701, Taiwan; 6 Institute of Biochemistry, Kaohsiung Medical
University, Kaohsiung, Taiwan; 6Department of Medical Laboratory Science
and Biotechnology, College of Medicine, National Cheng Kung University,
Tainan 701, Taiwan; 8Department of Urology, Kaohsiung Municipal Hsiao-
Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Purpose: Gemcitabine and cisplatin (GC) has beenwidely used for advanced
and metastatic urothelial carcinoma (UC). However, resistance to this rem-
edyhas been noticed.Wehave demonstrated that increase of TG-interacting
factor (TGIF) in specimens is associated withworse prognosis of upper tract
UC (UTUC) patients. The roles of TGIF in the gemcitabine resistance of UTUC
and a promising therapeutic strategy to UC were explored.
Materials and methods: Specimens of 23 UTUC patients who received GC
systemic chemotherapy were collected to evaluate the alterations of TGIF
in the resistance to the remedy by using immunohistochemistry. In vitro
characterizations of mechanismsmediating TGIF in gemcitabine resistance
were conducted by analyzing NTUB1 cells and their gemcitabine-resistant
sublines, NGR cells.
Results and conclusions: Increased TGIF and p-AKTSer473 are signiﬁcantly
associated with chemo-resistance, poor progression-free survival, and
higher cancer-related deaths of UTUC patients. Higher increases of TGIF, p-
AKTSer473, and invasive ability were demonstrated in NGR cells. Over-
expression of TGIF in NTUB1 cells upregulated p-AKTSer473 activation,
migration ability, and attenuated cellular sensitivity to gemcitabine.
Knockdown of TGIF in NGR cells downregulated p-AKTSer473 activation,
migration ability, and enhanced cellular sensitivity to gemcitabine. In
addition, histone deacetylases inhibitor trichostatin A (TSA) can inhibit
TGIF, p-AKTSer473 expression and migration ability. Synergistic effects of
gemcitabine and TSA on NGR cells were also demonstrated. Collectively,
TGIF contributes to the gemcitabine resistance of UTUC via AKT activation.
Combined treatment with gemcitabine and TSA might be a promising
therapeutic remedy to improve the gemcitabine resistance of UC.
MP5-9.
OVEREXPRESSION OF HEPATOMA-DERIVED GROWTH FACTOR (HDGF)
IS ASSOCIATED WITH WORSE PROGNOSIS IN UPPER URINARY TRACT
UROTHELIAL CARCINOMA
Bi-Wen Yeh 1,2, Wei-Ming Li 1,2,3,*, Ming-Hong Tai 4, Ching-Chia
Li 1,2,5, Chun-Nung Huang 1,2, Wen-Jeng Wu1,2,6,*. 1Department of
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University, Kaohsiung, Taiwan; 2Department of Urology, Kaohsiung Medical
University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;
3Department of Urology, Ministry of Health and Welfare Pingtung Hospital,
Pingtung, Taiwan; 4 Institute of Biomedical Sciences, National Sun Yat-Sen
University, Kaohsiung, Taiwan; 5Department of Urology, Kaohsiung
Municipal Ta-Tung Hospital, Kaohsiung, Taiwan; 6Department of Urology,
Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University,
Kaohsiung, Taiwan* Corresponding author.
* Corresponding author.Purpose: Hepatoma-derived growth factor (HDGF) is a nucleus targeted
growth factor, it has been reported to exertmitogenic effects on several types
of cells and elevated in various types of cancers suggesting an important role
in the development and progression of cancers. Our study was designed to
elucidate the correlation of HDGF expression and prognosis in patients with
upper urinary tract urothelial carcinoma (UTUC). The relatedmechanisms of
HDGF involved were investigated using urothelial cancer cell lines.
Patients and methods: One hundred and ﬁfty-eight UTUC specimens
were analyzed for HDGF by immunohistochemistry. HDGF expression in
urothelial cancer cell lines was analyzed by RT-PCR and western blotting.
In vitro characterizations of the cellular function of recombinant HDGF in
epithelial-mesenchymal transition (EMT) and tumorigenic behaviors were
performed by trans-well assay and colony formation assay, respectively.
Results and conclusion: Overexpression of HDGFwas present in 74 patients
(46.8%). A positive HDGF expressionwas signiﬁcantly associated with higher
disease progression (p¼ 0.036) and cancer-related death rates (p¼ 0.001). In
vitro study showed that overexpression of HDGF in non-invasive UC cells
could signiﬁcantly increase their cellular proliferation, colonies formation,
and migration/invasion ability through the PI3K/AKT pathway. In contrast,
knockdown of HDGF high expression UC cells with its speciﬁc shRNA
inhibited the growth ability using colonies formation experiments. These
results indicated that HDGF overexpression is associated with aggressive
biological behavior of UC cells via the PI3K/AKT pathway. In conclusion, our
study shown that HDGF is participated in UC disease progression processes.
HDGF can be a potential prognostic prediction biomarker for patients with
invasive UTUC post-operatively. Further identiﬁcation of the molecular
mechanisms involved and searching for speciﬁc targets related are warranted
MP5-10.
LONG TERM RENAL FUNCTION FOLLOWING NEPHROURETERECTOMY
IN UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA: 3 YEARS
EXPERIENCE
Chan-Jung Liu, Chien-Hui Ou, Wen-Horng Yang. National Cheng Kung
University Hospital Department of Urology, Taiwan
Purpose: This study is designed to evaluate the estimated glomerular
ﬁltration rate (eGFR) changes in patients undergoing radical nephro-ure-
terectomy (RNU) for upper tract urothelial carcinoma (UTUC).
Materials and methods: We retrospectively reviewed our patients with
upper urinary tract TCC undergone nephroureterectomy from 2007 to
2012. Only patients with upper urinary tract transitional cell carcinoma
(TCC) were enrolled in our study.We exclused the patients with end-stage-
renal disease. Total 72 patients had completed follow up for three years
after nephroureterectomy. The estimated glomerular ﬁltration rate (eGFR)
was calculated using the modiﬁed glomerular ﬁltration rate estimating
equation: eGFR (mL/min/1.73 m2) ¼ 175  Scr1.234  age0.179 ( 0.79 if
female). We compared eGFR before surgery and one year after surgery, two
years after surgery, and three years after surgery.
Results: Overall 72 patients were included in the study. The median age at
surgery was 66.46 (46e86) years. 31 patients (44%) had a preoperative
eGFRS 60mL/min per 1.73 m2 and 53 (75%) had an eGFRS 45mL/min per
1.73 m2. The preoperative CKD stage distribution was: CKD I (n ¼ 4, 5.5%),
CKD II (n ¼ 27, 37.5%), CKD III (n ¼ 33, 46%), and CKD IV (n ¼ 8, 11.1%). After
RNU,15 patients (20.8%) had a postoperative eGFRS 60mL/min per 1.73m2
and41 (56.9%)had aneGFRS45mL/minper1.73m2. Thepostoperative CKD
stages distributionwas: CKD I (n¼ 1,1%), CKD II (n¼ 14,19%), CKD III (n¼ 46,
64%), CKD IV (n¼ 5, 7%) and CKDV (n¼ 6, 8.3%). Comparison of preoperative
and postoperative Scr levels for each patient showed a mean difference of
0.44 mg/dL (P < 0.001), which represents a median (IQR) increase of 27.2%.
On similaranalysisperformed for eGFR,we foundameandifferencebetween
preoperative and postoperative eGFRof 10.8mL/min per 1.73m2 (P< 0.001),
which represents a median (IQR) decrease of 18.2 %. 3 years after RNU, 14
patients (19%) had a postoperative eGFRS 60 mL/min per 1.73 m2 and 37
(51.4%) had an eGFR S 45 mL/min per 1.73 m2. The long-term CKD stages
distributionwas: CKD I (n¼ 0, 0%), CKD II (n¼ 14,19%), CKD III (n¼ 38, 53%),
CKD IV (n ¼ 11, 22.2%) and CKD V (n ¼ 9, 12.5%). The eGFR decreased within
years as 58.06, 47.28, 45.68, and 41.91 mL/min per 1.73 m2 (P < 0.001).
Conclusions: TCCs located in the upper urinary tract had negative impact
on the ipsilateral renal function. eGFR was relatively low and furthermore,
it signiﬁcantly decreased within years after RNU.
